Dr Nick Maisey
- London, GB
- Best at: Bowel, oesophageal, stomach cancers, carcinoma of unknown primary & GIST
Dr Maisey is a consultant in Medical Oncology at Guy's and St Thomas’ NHS Foundation Trust (GSTT). He currently leads Medical Oncologist for oesophago-gastric cancer at GSTT and has held a number of key roles including service lead for colorectal cancer, vice chair of the upper gastrointestinal tumour working group and medical director for the South East London Cancer Network. He is currently a core member of the Oesophago-gastric priority group for the London Cancer Alliance, overseeing the delivery of care across North-West, South-West and South-East London. He is also a core member of the Carcinoma of unknown primary team at Guy's and St Thomas and have been instrumental in developing the service of treatments and pathways for this rare cancer. Dr Maisey is involved in cancer drug development and has been a principal investigator on a number of national clinical trials as well as commercial studies. After qualifying in 1993 from Guy's and St Thomas’ Hospital, he became a member of the Royal College of Physicians 1997. He completed his specialist training in medical oncology at the Royal Marsden Hospital. During his specialist training he was successful in a competitive grant from the National Cancer Institute to perform research at the Institute of Cancer Research in London. In 2002 he was awarded an MD thesis for his work on early response markers in Cancer.
Achievements of Dr Nick Maisey
Information about Dr Nick Maisey
Skills & Endorsements.
- oncology - 8
- chemotherapy - 5
colorectal cancer articles - Impact Factor
- gastrointestinal tract - 3
- oncology therapy - 3
oesophageal cancer articles - Impact Factor
- Oseophagus - 3
- oncology therapy - 3
Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
Neoadjuvant chemotherapy is established in the management of most resectable esophageal and esophagogastric junction adenocarcinomas. However, assessing the downstaging effects of chemotherapy and predicting response to treatment remain challenging, and the relative importance of tumor stage before and after chemotherapy is debatable.
Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer.
Sarcopenia and changes in body composition following neoadjuvant chemotherapy (NAC) may affect clinical outcome. We assessed the associations between CT body composition changes following NAC and outcomes in oesophageal cancer.
My recent video
Map of connections